miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Quintavalle, Cristina ^a,b   Mangani, Davide ^a   Roscigno, Giuseppina ^a,b   Romano, Giulia ^c   Diaz Lagares, Angel ^d   Iaboni, Margherita ^a   Donnarumma, Elvira ^c   Fiore, Danilo ^a   De Marinis, Pasqualino ^e   Soini, Ylermi ^f   Esteller, Manel ^d   Condorelli, Gerolama ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c IRCCS SDN   (Italy)

^d HOSPITAL DURAN I REYNALS   (Spain)

^e CARDARELLI HOSPITAL   (Italy)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 221; MICRORNA 222; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; MESSENGER RNA; MGMT PROTEIN, HUMAN; MICRORNA; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CELL DEATH; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENE TARGETING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; APOPTOSIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DNA DAMAGE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICRORNAS; RNA INTERFERENCE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 84884382332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074466     Document Type: Article

References (39)

1. Wen PY, Kesari S, (2008) Malignant Gliomas in Adults. N Engl J Med 359: 492-507. doi:10.1056/NEJMra0708126. PubMed: 18669428.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 114: 97-109. doi:10.1007/s00401-007-0243-4. PubMed: 17618441.
3. Stupp R, Hegi ME, (2013) Brain cancer in 2012: Molecular characterization leads the way. Nat Rev Clin Oncol 10: 69-70. doi:10.1038/nrclinonc.2012.240. PubMed: 23296110.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. doi:10.1056/NEJMoa043330. PubMed: 15758009.
5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466. doi:10.1016/S1470-2045(09)70025-7. PubMed: 19269895.
6. Mrugala MM, Chamberlain MC, (2008) Mechanisms of Disease: temozolomide and glioblastoma-look to the future. Nat Clin Pract Oncol 5: 476-486. doi:10.1038/ncpgasthep1210. PubMed: 18542116.
7. Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, et al. (2006) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26: 186-197. PubMed: 16819506.
8. Bignami M, O'Driscoll M, Aquilina G, Karran P, (2000) Unmasking a killer. DNA O6-methylguanine and the cytotoxicity of methylating agents. Mutat Res 462: 71-82.
9. Gerson SL, (2002) Clinical Relevance of MGMT in the Treatment of Cancer. J Clin Oncol 20: 2388-2399. doi:10.1200/JCO.2002.06.110. PubMed: 11981013.
10. Gerson SL, (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307. doi:10.1038/nrc1319. PubMed: 15057289.
11. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, et al. (2008) Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. J Clin Oncol 26: 4189-4199. doi:10.1200/JCO.2007.11.5964. PubMed: 18757334.
12. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, et al. (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101: 124-131. doi:10.1038/sj.bjc.6605127. PubMed: 19536096.
13. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, et al. (2007) Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606. doi:10.1093/brain/awm204. PubMed: 17785346.
14. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev Neurol 6: 39-51. doi:10.1038/nrneurol.2009.197.
15. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. doi:10.1038/nrc1997. PubMed: 17060945.
16. Gregory RI, Shiekhattar R, (2005) MicroRNA biogenesis and cancer. Cancer Res 65: 3509-3512. doi:10.1158/0008-5472.CAN-05-0298. PubMed: 15867338.
17. Garofalo M, Condorelli G, Croce CM, (2008) MicroRNAs in diseases and drug response. Curr Opin Pharmacol 8: 661-667. doi:10.1016/j.coph.2008.06.005. PubMed: 18619557.
18. Negrini M, Ferracin M, Sabbioni S, Croce CM, (2007) MicroRNAs in human cancer: from research to therapy. J Cell Sci 120: 1833-1840. doi:10.1242/jcs.03450. PubMed: 17515481.
19. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, et al. (2012) miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 31: 858-868. doi:10.1038/onc.2011.280. PubMed: 21743492.
20. Conti A, Aguennouz MH, Torre D, Tomasello C, Cardali S, et al. (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neuro Oncol 93: 325-332. doi:10.1007/s11060-009-9797-4. PubMed: 19159078.
21. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, et al. (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358. doi:10.1016/j.bbrc.2005.07.030. PubMed: 16039986.
22. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G, (2012) miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy. Curr Mol Med 12: 27-33. doi:10.2174/156652412798376170. PubMed: 22082479.
23. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498-509. doi:10.1016/j.ccr.2009.10.014. PubMed: 19962668.
24. Garofalo M, Condorelli GL, Croce CM, Condorelli G, (2010) MicroRNAs as regulators of death receptors signaling. Cell Death Differ: 2: 200-8. PubMed: 19644509.
25. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y-J, et al. (2011) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18: 74-82. doi:10.1038/nm.2577. PubMed: 22157681.
26. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. doi:10.1006/meth.2001.1262. PubMed: 11846609.
27. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG, (1999) Inactivation of the DNA Repair. Gene O6-Methylguanine-DNA Methyltransferase by Promoter Hypermethylation is a Common Event in Primary Human Neoplasia. Cancer Res 59: 793-797.
28. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, et al. (2012) miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol 14: 712-719. doi:10.1093/neuonc/nos089. PubMed: 22570426.
29. Blough MD, Zlatescu MC, Cairncross JG, (2007) O6-Methylguanine-DNA Methyltransferase Regulation by p53 in Astrocytic Cells. Cancer Res 67: 580-584. doi:10.1158/0008-5472.CAN-06-2782. PubMed: 17234766.
30. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, et al. (2006) MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13: 497-508. doi:10.1677/erc.1.01209. PubMed: 16728577.
31. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, et al. (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neuro Oncol 93: 325-332. doi:10.1007/s11060-009-9797-4. PubMed: 19159078.
32. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107: 264-269. doi:10.1073/pnas.0907904107. PubMed: 20018759.
33. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, et al. (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358. doi:10.1016/j.bbrc.2005.07.030. PubMed: 16039986.
34. Sakumi K, Shiraishi A, Shimizu S, Tsuzuki T, Ishikawa T, et al. (1997) Methylnitrosourea-induced Tumorigenesis in MGMT Gene Knockout Mice. Cancer Res 57: 2415-2418. PubMed: 9192819.
35. Sandercock LE, Hahn JN, Li L, Luchman HA, Giesbrecht JL, et al. (2008) Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 29: 866-874. doi:10.1093/carcin/bgn030. PubMed: 18281247.
36. Takagi Y, Takahashi M, Sanada M, Ito R, Yamaizumi M, et al. (2003) Roles of MGMT and MLH1 proteins in alkylation-induced apoptosis and mutagenesis. DNA Repair (Amst) 2: 1135-1146. doi:10.1016/S1568-7864(03)00134-4. PubMed: 13679151.
37. Walter CA, Lu J, Bhakta M, Mitra S, Dunn W, et al. (1993) Brain and liver targeted overexpression of O6-methylguanine DNA methyltransferase in transgenic mice. Carcinogenesis 14: 1537-1543. doi:10.1093/carcin/14.8.1537. PubMed: 8353838.
38. Reese JS, Allay E, Gerson SL, (2001) Overexpression of human O6-alkylguanine DNA alkyltransferase(AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice. Oncogene 20: 5258-5263.
39. Allay E, Veigl M, Gerson SL, (1999) Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene 18: 3783-3787.